Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung
Ardizzoni, A.; Canobbio, L.; Pronzato, P.; Rubagotti, A.; De Palma, M.; Baracco, F.; Serrano, J.; Serrano, S.; Faravelli, B.; Nosenzo, M.
Cancer Treatment Reports 70(7): 891-892
1986
ISSN/ISBN: 0361-5960 PMID: 3719580 Document Number: 284499
Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status less than or equal to 2; weight loss less than or equal to 10%; age less than or equal to 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.